Federated Hermes
HZNP

Federated Hermes’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Federated Hermes’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-95,953
Closed -$10.9M – 2327
2022
Q4 		$10.9M Sell
95,953
-89,181
-48% -$7.41M 0.03% 520
2022
Q3 		$11.5M Sell
185,134
-93,333
-34% -$6.52M 0.03% 499
2022
Q2 		$22.2M Sell
278,467
-19,328
-6% -$1.83M 0.06% 363
2022
Q1 		$31.3M Buy
297,795
+12,011
+4% +$1.17M 0.07% 338
2021
Q4 		$30.8M Buy
285,784
+3,060
+1% +$334K 0.06% 375
2021
Q3 		$31M Sell
282,724
-76,938
-21% -$7.99M 0.06% 377
2021
Q2 		$33.7M Buy
359,662
+568
+0.2% +$52.3K 0.06% 363
2021
Q1 		$33.1M Sell
359,094
-139,894
-28% -$11.8M 0.06% 374
2020
Q4 		$36.5M Sell
498,988
-20,893
-4% -$1.55M 0.07% 313
2020
Q3 		$40.4M Buy
519,881
+6,169
+1% +$424K 0.09% 243
2020
Q2 		$28.6M Buy
513,712
+365,846
+247% +$15.7M 0.07% 316
2020
Q1 		$4.38M Sell
147,866
-205,777
-58% -$6.96M 0.01% 667
2019
Q4 		$12.8M Sell
353,643
-30,188
-8% -$926K 0.03% 542
2019
Q3 		$10.5M Sell
383,831
-262,461
-41% -$6.79M 0.03% 562
2019
Q2 		$15.6M Buy
646,292
+351,439
+119% +$8.91M 0.04% 422
2019
Q1 		$7.79M Sell
294,853
-223,401
-43% -$5.29M 0.02% 653
2018
Q4 		$10.1M Sell
518,254
-234,995
-31% -$4.61M 0.03% 484
2018
Q3 		$14.7M Sell
753,249
-28,821
-4% -$548K 0.03% 438
2018
Q2 		$13M Buy
782,070
+142,203
+22% +$2.17M 0.04% 372
2018
Q1 		$9.09M Buy
639,867
+374,107
+141% +$5.53M 0.03% 458
2017
Q4 		$3.88M Buy
+265,760
New +$3.73M 0.01% 692
2017
Q2 		– Sell
-38,790
Closed -$573K – 2222
2017
Q1 		$573K Sell
38,790
-18,512
-32% -$300K ﹤0.01% 1303
2016
Q4 		$927K Sell
57,302
-13,101
-19% -$238K ﹤0.01% 1156
2016
Q3 		$1.28M Buy
+70,403
New +$1.38M ﹤0.01% 1030

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Federated Hermes's HZNP Position: Q1 2023 in Review

Federated Hermes sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 95,953 shares — an estimated $10.9M sold.

Federated Hermes first reported a position in HZNP in Q3 2016 and held it in 24 quarters. The position peaked at $40.4M in Q3 2020. 552 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Federated Hermes reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 95,953 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $10.9M.
  • Federated Hermes first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 24 quarters.
  • Federated Hermes's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $40.4M in Q3 2020.
  • 552 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.